The clinical results from several trials suggest that patients get a high response rate from enfortumab vedotin (the antibody-drug conjugate) that is made durable from pembrolizumab (the checkpoint ...

Immune checkpoint inhibitors have revolutionized cancer treatment, yet many tumours develop strategies to evade or suppress immune responses, limiting long-term efficacy. This webcast will examine how ...

Immune Checkpoint Blockade in Deficient Mismatch Repair/Microsatellite Instability-High Gastric Cancer: Solid Evidence or Premature Extrapolation? The following represents disclosure information ...

This session, from the 2025 IO360 Summit, focuses on different strategies to augment immune response in urothelial carcinoma, presented by Dr Jonathan Rosenberg, Memorial Sloan Kettering Cancer Center ...

Researchers at The University of Texas MD Anderson Cancer Center have identified an epigenetic target for replication stress, called DPY30, that could sensitize pancreatic tumors to immunotherapy and ...